Ever Fortune. AI Co

Ever Fortune. AI Co AAQS

The The AAQS of Ever Fortune. AI Co (6841.TWO) as of Oct 23, 2026 is 3. In the previous year, The AAQS was 3.00 — a change of 0.00% (lower).

AAQS

3

YoY

0.00%

Last updated:

Ever Fortune. AI Co has a current AAQS of 3.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Ever Fortune. AI Co in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Ever Fortune. AI Co AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
3.00 TWD
Jan 1, 2019
3.00 TWD
Jan 1, 2020
3.00 TWD
Jan 1, 2021
3.00 TWD
Jan 1, 2022
3.00 TWD
Jan 1, 2023
3.00 TWD
Jan 1, 2024
3.00 TWD
Jan 1, 2025
3.00 TWD
The Ever Fortune. AI Co AAQS history
YEARAAQSYoY
30.00%
30.00%
30.00%
30.00%
30.00%
30.00%
30.00%
3—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ever Fortune. AI Co Stock analysis

What does Ever Fortune. AI Co do? Ever Fortune.AI Co., Ltd. generates revenue through the sale of medical AI software products and customized technology solutions. The company offers medical big data platforms, cloud biomedical services, and AI-driven tools such as the radiographic bone age-assisted interpretation system, ultrasound breast tumor auxiliary classification system, and CT liver cancer metastasis risk management system. These products target healthcare providers, hospitals, and medical institutions seeking advanced diagnostic and analytical capabilities. The firm's focus on specialized medical AI applications ensures consistent demand from clients requiring precision in radiology, oncology, and cardiology. The company's revenue streams include the provision of medical AI data analysis services and tailored AI technology solutions for healthcare facilities. Products like the liver fibrosis evaluation system and irregular cardiac fibrillation interpretation system are designed to address specific clinical needs, enhancing diagnostic accuracy. Healthcare organizations, particularly those in radiology and cardiology departments, purchase these tools to improve patient outcomes and operational efficiency. Ever Fortune.AI's business model centers on delivering high-value AI solutions for medical diagnostics, with a portfolio that includes both standardized products and custom-developed systems. The firm's offerings cater to hospitals and medical institutions looking to integrate AI into their diagnostic workflows. By focusing on niche medical applications, the company establishes itself as a specialized provider in the healthcare technology sector. Ever Fortune. AI Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ever Fortune. AI Co stock

The AAQS of Ever Fortune. AI Co is 3 in 2025.

On Eulerpool you can find the complete historical development of The AAQS Ever Fortune. AI Co since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Ever Fortune. AI Co

All Key Metrics — Ever Fortune. AI Co